IIN IntriCon

IntriCon Repositions its Hearing Aid Sales in the UK through New Distribution Agreement, Sells Accessory Business Assets of UK Limited Subsidiary

IntriCon Repositions its Hearing Aid Sales in the UK through New Distribution Agreement, Sells Accessory Business Assets of UK Limited Subsidiary

Shift Enables Significant Cost Reduction and Reallocation of Resources in Value-based Hearing Health

ARDEN HILLS, Minn., July 02, 2019 (GLOBE NEWSWIRE) -- IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced it has entered into a distribution agreement with Puretone Ltd., a Rochester, UK-based hearing health company with operations in more than 75 countries. Under the terms of the agreement, Puretone will distribute IntriCon branded hearing aids into the National Health Service system on the Company’s behalf.

Additionally, IntriCon completed the sale of its PC Werth accessory business assets to Warner Tech-care UK LTD, a subsidiary of US based Warner Tech-care LLC. Warner will continue to sell the accessories and services under the PC Werth brand names in the region. 

In connection with the distribution agreement and sale of assets, IntriCon ceased all production and direct sales activities at its UK Limited subsidiary, effective June 28, 2019. The closure is expected to provide the Company with a cost reduction of approximately $1.0 million annually. 

“We are delighted to partner with Puretone. They are a well-respected, global hearing health provider that has a proven track record for reaching the UK’s substantial customer base,” said Mark Gorder, President and Chief Executive Officer. “Importantly, this shift from direct sales to a distribution model in the UK not only provides us with a reduced cost structure but enables us to better focus our resources on our value-based hearing healthcare opportunities, most notably the large emerging OTC hearing aid market in the US.”

About IntriCon Corporation

Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature and micro-miniature body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better-connected devices. IntriCon has facilities in the United States, Asia and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about IntriCon, visit .

Investor Relations Contact                                                              

Leigh Salvo                                   

(415) 937-5404    

EN
02/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IntriCon

 PRESS RELEASE

Intricon Announces Completion of Acquisition by an Affiliate of Altari...

Intricon Announces Completion of Acquisition by an Affiliate of Altaris Capital Partners Investment by Altaris Supports Intricon’s Ability to Deliver Innovative Solutions and Service to its Customers ARDEN HILLS, Minn., May 24, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced the completion of its acquisition by funds affiliated with Altaris Capital Partners, LLC (toget...

 PRESS RELEASE

Intricon Reports Fourth Quarter and Full Year 2021 Results

Intricon Reports Fourth Quarter and Full Year 2021 Results ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior year...

 PRESS RELEASE

Intricon Enters into Agreement to be Acquired by an Affiliate of Altar...

Intricon Enters into Agreement to be Acquired by an Affiliate of Altaris Capital Partners for $241 Million Intricon Shareholders to Receive $24.25 Per Share in Cash ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced that it has entered into a definitive agreement whereby an affiliate of Altaris Capital Partners, LLC (collectively with its affi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: January 29, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: January 24, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch